Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development Product

Monday, October 2, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

-- Drug-device combination therapy for inhaled pharmaceutical-grade xenon gas under investigation to lessen brain damage, improve survival and function in patients suffering cardiac arrest --



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook